Thailand · Delayed Price · Currency is THB X Bioscience PCL Statistics
Total Valuation
BKK:XBIO has a market cap or net worth of THB 972.08 million. The enterprise value is 1.13 billion.
| Market Cap | 972.08M |
| Enterprise Value | 1.13B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BKK:XBIO has 12.15 billion shares outstanding. The number of shares has increased by 5,438.62% in one year.
| Current Share Class | 12.15B |
| Shares Outstanding | 12.15B |
| Shares Change (YoY) | +5,438.62% |
| Shares Change (QoQ) | +1,539.16% |
| Owned by Insiders (%) | 85.85% |
| Owned by Institutions (%) | n/a |
| Float | 1.71B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.10 |
| PB Ratio | 2.95 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 0.54.
| Current Ratio | 0.97 |
| Quick Ratio | 0.36 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.54 |
| Interest Coverage | -17.20 |
Financial Efficiency
Return on equity (ROE) is -129.90% and return on invested capital (ROIC) is -92.37%.
| Return on Equity (ROE) | -129.90% |
| Return on Assets (ROA) | -26.37% |
| Return on Invested Capital (ROIC) | -92.37% |
| Return on Capital Employed (ROCE) | -115.11% |
| Weighted Average Cost of Capital (WACC) | 4.47% |
| Revenue Per Employee | 399,216 |
| Profits Per Employee | -1.86M |
| Employee Count | 399 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 13.28 |
Taxes
| Income Tax | -12.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.67% in the last 52 weeks. The beta is -0.18, so BKK:XBIO's price volatility has been lower than the market average.
| Beta (5Y) | -0.18 |
| 52-Week Price Change | -91.67% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 50.81 |
| Average Volume (20 Days) | 6,897,550 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BKK:XBIO had revenue of THB 159.29 million and -742.29 million in losses. Loss per share was -0.06.
| Revenue | 159.29M |
| Gross Profit | 64.20M |
| Operating Income | -433.66M |
| Pretax Income | -749.02M |
| Net Income | -742.29M |
| EBITDA | -431.66M |
| EBIT | -433.66M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 28.08 million in cash and 178.18 million in debt, with a net cash position of -150.11 million or -0.01 per share.
| Cash & Cash Equivalents | 28.08M |
| Total Debt | 178.18M |
| Net Cash | -150.11M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 330.01M |
| Book Value Per Share | 0.03 |
| Working Capital | -8.20M |
Cash Flow
In the last 12 months, operating cash flow was -107.31 million and capital expenditures -8.71 million, giving a free cash flow of -116.02 million.
| Operating Cash Flow | -107.31M |
| Capital Expenditures | -8.71M |
| Depreciation & Amortization | 2.01M |
| Net Borrowing | -121.78M |
| Free Cash Flow | -116.02M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 40.31% |
| Operating Margin | -272.25% |
| Pretax Margin | -470.23% |
| Profit Margin | n/a |
| EBITDA Margin | -270.99% |
| EBIT Margin | -272.25% |
| FCF Margin | n/a |
Dividends & Yields
BKK:XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5,438.62% |
| Shareholder Yield | -5,438.62% |
| Earnings Yield | -76.36% |
| FCF Yield | -11.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 3, 2025. It was a reverse split with a ratio of 0.1428571429.
| Last Split Date | Oct 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1428571429 |
Scores
BKK:XBIO has an Altman Z-Score of -5.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.75 |
| Piotroski F-Score | 3 |